387827-19-2

Basic information

• Product Name: 4-(3-AMINO-PHENYL)-PIPERIDINE-1-CARBOXYLIC ACID TERT-BUTYL ESTER
• Synonyms: 4-(3-AMINO-PHENYL)-PIPERIDINE-1-CARBOXYLIC ACID TERT-BUTYL ESTER;TERT-BUTYL 4-(3-AMINOPHENYL)PIPERIDINE-1-CARBOXYLATE;N-BOC-4-(3-AMINOPHENYL) PIPERIDINE;1-Piperidinecarboxylic acid, 4-(3-aMinophenyl)-, 1,1-diMethylethyl ester;Tert-butyl 4-[3-(amino)phenyl]-1-Piperidinecarboxylate;tert-Butyl 4-(3-aminophenyl)
• CAS NO: 387827-19-2
• Molecular Formula: C₁₆H₂₄N₂O₂
• Molecular Weight: 276.37
• Product Categories: pharmacetical
• Mol File: 387827-19-2.mol

Chemical Properties

• Boiling Point: 413.217°C at 760 mmHg
• Flash Point: 203.706°C
• Appearance: /
• Density: 1.1g/cm³
• Vapor Pressure: 0mmHg at 25°C
• Refractive Index: 1.551
• Storage Temp.: Keep in dark place,Inert atmosphere,Room temperature
• PKA: 4.60±0.10(Predicted)
• CAS DataBase Reference: 4-(3-AMINO-PHENYL)-PIPERIDINE-1-CARBOXYLIC ACID TERT-BUTYL ESTER(CAS DataBase Reference)
• NIST Chemistry Reference: 4-(3-AMINO-PHENYL)-PIPERIDINE-1-CARBOXYLIC ACID TERT-BUTYL ESTER(387827-19-2)
• EPA Substance Registry System: 4-(3-AMINO-PHENYL)-PIPERIDINE-1-CARBOXYLIC ACID TERT-BUTYL ESTER(387827-19-2)

Safety Data

• Hazardous Substances Data: 387827-19-2(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Synthesis:
4-(3-Amino-phenyl)-piperidine-1-carboxylic acid tert-butyl ester is used as an intermediate in the synthesis of various pharmaceuticals for its ability to contribute to the formation of complex molecular structures. Its presence in the synthesis process can lead to the development of new drugs with specific therapeutic properties.
Used in Organic Chemistry Research:
In the field of organic chemistry, 4-(3-Amino-phenyl)-piperidine-1-carboxylic acid tert-butyl ester is utilized as a research compound to explore its reactivity and potential to form new chemical entities. This can lead to advancements in understanding organic reactions and the creation of novel organic compounds.
Used in Biotechnology Applications:
4-(3-Amino-phenyl)-piperidine-1-carboxylic acid tert-butyl ester is employed in the biotechnology industry for its potential to be integrated into biotechnological processes. Its unique structure may offer new ways to interact with biological systems, possibly leading to the development of new bioactive molecules or enhancing existing ones.
Used in Drug Development:
In drug development, 4-(3-Amino-phenyl)-piperidine-1-carboxylic acid tert-butyl ester serves as a key component in the design and synthesis of new drug candidates. Its presence in the molecular structure can influence the pharmacokinetics, pharmacodynamics, and overall efficacy of the drug, making it a valuable asset in the drug discovery process.

InChI:InChI=1/C16H24N2O2/c1-16(2,3)20-15(19)18-9-7-12(8-10-18)13-5-4-6-14(17)11-13/h4-6,11-12H,7-10,17H2,1-3H3

Upstream product

• 138647-55-9 tert-butyl 1,2,3,6-tetrahydro-4-(3-nitrophenyl)pyridine-1-carboxylate 
• 387827-18-1 tert-butyl 4-[3-(amino)phenyl]-1,2,3,6-tetrahydro-1-pyridinecarboxylate 
• 75-31-0 isopropylamine 
• 79099-07-3 N-tert-butyloxycarbonylpiperidin-4-one 
• 1510865-58-3 tert-butyl 4-(3-nitrophenyl)piperidine-1-carboxylate 
• 591-19-5 m-Bromoaniline 
• 375853-82-0 tert-Butyl 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-3,6-dihydro-1(2H)-pyridinecarboxylate 
• 585-79-5 m-nitrobromobenzene 

Downstream Products

• 291289-49-1 4-(3-aminophenyl)piperidine 
• 486445-48-1 N-(3-(piperidine-4-yl)phenyl)propionamide 

Relevant articles and documents

BRAF DEGRADERS

Present invention provides compounds that cause specifically the degradation of BRAF. The present compounds are useful for the treatment of various cancers.

TARGETED PROTEIN DEGRADATION

This invention provides pharmaceutical protein degraders and E3 ubiquitin ligase binders for therapeutic applications as described further herein.

Practical synthesis of pharmaceutically relevant molecules enriched in sp3 character

The expedient synthesis of compounds enriched in sp3 character is key goal in modern drug discovery. Herein, we report how a single pot Suzuki-Miyaura-hydrogenation can be used to furnish lead and fragment-like products in good to excellent yields. The approach has been successfully applied in formats amenable to parallel synthesis, in an asymmetric sense, and in the preparation of molecules with annotated biological activity.

Pyrimidine derivative, preparation method therefor and application thereof in medicine

The invention relates to a pyrimidine derivative, a preparation method therefor and an application thereof in medicine. Particularly, the invention relates to a compound as shown in general formula (M) or a stereisomer, an aquo-complex, a metabolic product, a solvate, a pharmaceutically acceptable salt, a co-crystallization or a prodrug thereof; the preparation method thereof; and the application of the medicine composition thereof and the compound medicine compound in the medicine, particularly the application as an EGFR target spot inhibitor, wherein the definition of each substituent group in the general formula (M) is the same as that of the specification.

PREPARATION AND USES OF 1,2,4-TRIAZOLO [1,5a] PYRIDINE DERIVATIVES

This application relates to compounds of the general Formula I and salts thereof, wherein X, R1A, R1B, R2, R3, R4, and R5 are as defined herein. The application also relates to compositions and methods of treatment of hyperproliferative diseases or disorders.

Arylthiobenzylpiperidine derivatives

This invention is directed to Arylthiobenzylpiperidine derivatives which are ligands at the MCH1 receptor. The invention provides a pharmaceutical composition comprising a therapeutically effective amount of a compound of the invention and a pharmaceutically acceptable carrier. This invention also provides a pharmaceutical composition made by admixing a therapeutically effective amount of a compound of the invention and a pharmaceutically acceptable carrier. This invention further provides a process for making a pharmaceutical composition comprising combining a therapeutically effective amount of a compound of the invention and a pharmaceutically acceptable carrier. This invention also provides a method of treating a subject suffering from depression and/or anxiety which comprises administering to the subject an amount of a compound of the subject invention. This invention also provides a method of treating a subject suffering from obesity which comprises administering to the subject an amount of a compound of the subject invention.

MEDICINAL USE OF RECEPTOR LIGANDS

Compounds of formula (I) are ligands of the melanin concentrating hormone-1 receptor (MCH-1 R), useful in the treatment of diseases responsive to modulation of melanin concentrating hormone (MCH) activity, for example feeding disorders and diseases for which obesity is a risk factor (I): wherein ring B is selected from specific substituted phenyl or benz-fused 5-membered N-containing heterocycles defined in the specification; R, is attached to a ring carbon of ring B, and represents hydrogen, F, Cl, or -OCH3; X is =CH- or =N-; L, is -CH2- or -CH2CH2- ; L2 is a bond, -CH2- or -CO-; R2 is H or C,-C3 alkyl, or -N(R2) L,- is selected from specific cyclic amino linker radicals as defined in the specification; ring A is selected from specific N- containing heterocyclic rings as defined in the specification.

4-Aryl piperidines

This invention is directed to 4-aryl piperidines and related heterocyclic compounds which are selective antagonists for melanin concentrating hormone-1 (MCH1) receptors. The invention provides a pharmaceutical composition comprising a therapeutically effective amount of the compound of the invention and a pharmaceutically acceptable carrier. This invention provides a pharmaceutical composition made by combining a therapeutically effective amount of the compound of this invention and a pharmaceutically acceptable carrier. This invention further provides a process for making a pharmaceutical composition comprising combining a therapeutically effective amount of the compound of the invention and a pharmaceutically acceptable carrier. This invention also provides a method of reducing the body mass of a subject which comprises administering to the subject an amount of a compound of the invention effective to reduce the body mass of the subject. This invention further provides a method of treating a subject suffering from depression and/or anxiety which comprises administering to the subject an amount of a compound of the invention effective to treat the subject''s depression and/or anxiety.

4-aryl piperidines

This invention is directed to 4-aryl piperidines and related heterocyclic compounds which are selective antagonists for melanin concentrating hormone-1 (MCH1) receptors. The invention provides a pharmaceutical composition comprising a therapeutically effective amount of the compound of the invention and a pharmaceutically acceptable carrier. This invention provides a pharmaceutical composition made by combining a therapeutically effective amount of the compound of this invention and a pharmaceutically acceptable carrier. This invention further provides a process for making a pharmaceutical composition comprising combining a therapeutically effective amount of the compound of the invention and a pharmaceutically acceptable carrier. This invention also provides a method of reducing the body mass of a subject which comprises administering to the subject an amount of a compound of the invention effective to reduce the body mass of the subject. This invention further provides a method of treating a subject suffering from depression and/or anxiety which comprises administering to the subject an amount of a compound of the invention effective to treat the subject's depression and/or anxiety.

DNA encoding a human melanin concentrating hormone receptor (MCH1) and uses thereof

This invention provides an isolated nucleic acid encoding a human MCH1 receptor, a purified human MCH1 receptor, vectors comprising isolated nucleic acid encoding a human MCH1 receptor, cells comprising such vectors, antibodies directed to a human MCH1 receptor, nucleic acid probes useful for detecting nucleic acid encoding human MCH1 receptors, antisense oligonucleotides complementary to unique sequences of nucleic acid encoding human MCH1 receptors, transgenic, nonhuman animals which express DNA encoding a normal or mutant human MCH1 receptor, methods of isolating a human MCH1 receptor, methods of treating an abnormality that is linked to the activity of a human MCH1 receptor, as well as methods of determining binding of compounds to mammalian MCH1 receptors. This invention further provides a method of treating a subject suffering from urinary incontinence which comprises administering to the subject an amount of an MCH1 antagonist effective to treat the subject's urinary incontinence.